Ignite Creation Date:
2024-05-06 @ 6:55 PM
Last Modification Date:
2024-10-26 @ 2:57 PM
Study NCT ID:
NCT05830084
Status:
RECRUITING
Last Update Posted:
2023-05-11
First Post:
2023-04-13
Brief Title:
Phase Ib Regorafenib With Conventional ChemotherapyNewly Diagnosed Patients Multimetastatic Ewing Sarcoma
Sponsor:
Gustave Roussy Cancer Campus Grand Paris
Organization:
Gustave Roussy Cancer Campus Grand Paris
Organization Data
Organization:
Gustave Roussy Cancer Campus Grand Paris
Class:
OTHER
Study ID:
2022-002874-10
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Gustave Roussy Cancer Campus Grand Paris
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Bayer | INDUSTRY |